Sr.Stat programmer clin pharm

Syneos Health® is a leading fully-integrated life sciences services organization built to accelerate customer success. We partner with innovators at every point across the drug development and commercialization continuum, helping them navigate complexity, anticipate change and accelerate progress.

Our Clinical Solutions team members act with a drug development mindset, applying their years of experience and deep expertise to truly understand customer needs and represent those in the solutions we shape.

Whether you join us in a Functional Service Provider partnership or a Full-Service environment, you’ll collaborate with passionate problem solvers, innovating as a team to help our customers achieve their goals. We are agile and driven to deliver – for one another, our customers, and, most importantly, for those in need.

Discover what your 25,000 future colleagues already know:

Why Syneos Health
• We are passionate about developing our people, through career development and progression; supportive and engaged line management; technical and therapeutic area training; peer recognition and total rewards program.
• We are committed to building an inclusive culture – where you can authentically be yourself. Central to this is our purpose – Driven to Deliver – which captures the passion of our colleagues to show up each day and shape solutions that have the ability to dramatically impact someone’s life.
• We are continuously building the company we all want to work for and our customers want to work with. Why? Because we know that when we bring together smart colleagues from across the world, we can shape the future of healthcare, driving impact for customers and defining the pace of patient progress.

Job Responsibilities

Uses SAS or other software to develop custom programming code to generate summary tables, data listings, graphs and derived datasets as specified in the statistical analysis plan and programming specifications.
Works to ensure that outputs meet quality standards and project requirements. Performs validation programming and works with other Programmers, Biostatisticians, and other project team members to resolve discrepancies or any findings. Keeps project team members informed of programming progress and issues requiring their attention. Follow applicable SOPs, WIs, and relevant regulatory guidelines (e.g. ICH).
Maintains well organized, complete, and up-to-date project documentation, testing, and verification/quality control documents and programs ensuring inspection readiness.
Manages scheduling and time constraints across multiple projects at a time, sets goals based on priorities from management, and adapts to timeline or priority changes by reorganizing daily workload. Develops specifications for datasets and outputs of any complexity according to statistical and sponsor requirements. Anticipates and addresses potential programming issues, reflects forethought, establishes the basis for efficient programming and accurately defines all variables to be accepted by peer review and sponsor/requestor with little rework.
Prepares in advance for internal meetings, contributes ideas, and demonstrates respect for opinions of others.
Conducts effective internal meetings (appropriate in format, frequency and attendance). Distributes relevant information in advance. Ensures minutes are promptly and accurately distributed. Follows action items through to completion, and maintains order and focus of meetings, working toward consensus. Displays willingness to work with others and assist with projects and initiatives as necessary to meet the needs of the business. Negotiates and establishes accurate time estimates for completion of study programming activities with internal team members and statistical programming management, and completes project programming activities within timeframe allotted.
Acts as the lead statistical programmer. Directs the programming activities of other programming personnel and monitors progress on programming deliverables. Reviews project documentation such as Statistical Analysis Plan, mock shells, programming specifications, annotated CRFs, and SAS database design. Provides feedback to the appropriate project team members which reflects forethought and reduces inefficiencies in programming activities.
Participates in sponsor meetings, kickoff meetings, and bid defense meetings as statistical programming representative, as required by sponsor. Contributes to the mentoring of programming personnel through developing training courses, presenting training materials, reviewing work, and providing feedback or guiding new associates in process. Transfers deliverables. Performs other work-related duties as assigned.
Minimal travel may be required

Qualifications:

Undergraduate degree, preferably in a scientific or statistical discipline; in lieu of degree, an equivalent combination of education and demonstrated programming experience.
Extensive programming experience in SAS or other required software, preferably in a clinical trial environment.
Excellent written and verbal communication skills.
Ability to read, write, speak and understand English.

Get to know Syneos Health

Over the past 5 years, we have worked with 94% of all Novel FDA Approved Drugs, 95% of EMA Authorized Products and over 200 Studies across 73,000 Sites and 675,000+ Trial patients.

No matter what your role is, you’ll take the initiative and challenge the status quo with us in a highly competitive and ever-changing environment. Learn more about Syneos Health.

http://www.syneoshealth.com

Additional Information

Tasks, duties, and responsibilities as listed in this job description are not exhaustive. The Company, at its sole discretion and with no prior notice, may assign other tasks, duties, and job responsibilities. Equivalent experience, skills, and/or education will also be considered so qualifications of incumbents may differ from those listed in the Job Description. The Company, at its sole discretion, will determine what constitutes as equivalent to the qualifications described above. Further, nothing contained herein should be construed to create an employment contract. Occasionally, required skills/experiences for jobs are expressed in brief terms. Any language contained herein is intended to fully comply with all obligations imposed by the legislation of each country in which it operates, including the implementation of the EU Equality Directive, in relation to the recruitment and employment of its employees. The Company is committed to compliance with the Americans with Disabilities Act, including the provision of reasonable accommodations, when appropriate, to assist employees or applicants to perform the essential functions of the job.

About the company

Syneos Health provides end-to-end biopharmaceutical solutions across the clinical-to-commercial spectrum. It helps biopharma companies, healthcare organizations, and investors by offering specialized expertise, insights, and technology-enabled services to move therapies faster to patients. Its offerings include Kinetic, a modern omnichannel customer engagement platform that uses targeting and analytics to coordinate nationwide healthcare communications, and Syneos One, an asset development approach that aligns strategy and execution from early concept through commercialization. The company uses AI and advanced tech to improve performance and reduce risk in drug development and market delivery. Its goal is to be a trusted partner that accelerates therapy development and delivery by combining scientific know-how with integrated, data-driven services.

Company Size

10,001+

Company Stage

IPO

Headquarters

Morrisville, North Carolina

Founded

1985

Get referred to Syneos Health

See people who can refer or advise you

Simplify's Take

What believers are saying

KAI partnership on April 30, 2026 expands commercial intelligence for U.S. pharma launches.
Syneos says Causaly cut study-design insight time roughly 50% in 2026.
Databricks reduced source-data review from days to hours, speeding trial interventions.

What critics are saying

March 31, 2026 Kempen discovery keeps securities-fraud claims alive over backlog reporting.
Syneos Italy announced 49 layoffs on March 25, 2026, signaling operating pressure.
A sustained data-integrity finding in Kempen would damage sponsor trust and trigger defections.

What makes Syneos Health unique

Syneos combines clinical development and commercialization under one roof, unlike pure-play CROs.
August 18, 2026 AI stack spans Causaly, Databricks, and Microsoft across workflows.
More than 280 Microsoft Copilot agents give Syneos broad internal automation depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Employee Stock Purchase Plan
Flexible Work Hours
Paid Vacation
Paid Sick Leave
Remote Work Options

Company News

TransportTalk

Aug 31st, 2026

Teletrac Navman appoints Sara Epstein to senior leadership role.

Teletrac Navman appoints Sara Epstein to senior leadership role. Reading Time: 2 mins read Teletrac Navman has appointed Sara Epstein as chief legal and administrative officer as the connected mobility business enters its next phase of growth. Epstein brings more than 20 years of legal and executive leadership experience across sectors including healthcare, life sciences, pharmacy and logistics. She will oversee Teletrac Navman's legal, compliance, data privacy and governance functions, along with People and Culture and Health and Safety. Epstein was previously chief legal officer at pharmacy benefits company RxBenefits and executive vice president and deputy general counsel at Syneos Health, where she led a global team responsible for legal and privacy services. She has also held senior legal roles at Cotiviti Holdings and BlueLinx Holdings and was an associate at international law firm Jones Day. Teletrac Navman President and chief executive Alain Samaha says Epstein's experience will support the company's strategic and growth plans. "Sara brings a powerful combination of legal acumen, business judgment and executive leadership that will help accelerate our strategic initiatives and support our long-term growth," Samaha says. "Her experience leading global teams and navigating complex business environments will be instrumental as we continue to drive innovation, strengthen our customer relationships and execute on our growth ambitions. We're thrilled to welcome her to the team." The appointment follows Teletrac Navman's acquisition by Respida Capital earlier this year and a series of product developments, including the launch of Energy Hub within its TN360 fleet management platform and the company's Electronic Braking Performance Monitoring System. "I'm excited to join Teletrac Navman at such an important time in the company's evolution," Epstein says. "The organisation has a strong foundation, a talented global team, and a clear vision for growth. I look forward to working across the business to support our strategic priorities and contribute to the next chapter of Teletrac Navman's success." Epstein holds a Juris Doctor from Tulane University Law School and a bachelor's degree from Tufts University.

HR TODAY

Aug 26th, 2026

Madhuri Raya joins Syneos Health as Global Head, AI & Engineering and Technology Capability Center.

Madhuri Raya joins Syneos Health as Global Head, AI & Engineering and Technology Capability Center. Hyderabad, Telangana, India, August 2026 - Syneos Health has appointed Madhuri Raya as Global Head, AI & Engineering and Technology Capability Center, strengthening its technology leadership as the organisation accelerates its AI-enabled strategy. In her new mandate, Raya will focus on scaling engineering capabilities behind Syneos Health's growing AI ecosystem and helping translate technology innovation into practical solutions for biopharmaceutical development. Raya brings more than two decades of experience across software engineering, product engineering, cloud-native technologies, AI/ML-enabled solutions and global engineering leadership. She joins Syneos Health after a long tenure with Optum, where she most recently served as Vice President of Software Engineering. During more than eight years with the organisation, she progressed through senior technology leadership positions, including Director of Product Engineering and Senior Director - Product Engineering. Before Optum, Raya spent more than five years with UnitedHealth Group, serving as Engineering Manager and subsequently Senior Engineering Manager. These roles added to her experience in leading engineering organisations within the healthcare ecosystem and managing increasingly complex technology responsibilities. Earlier in her career, Raya spent more than a decade with the Robert Bosch Research and Technology Center. She worked initially as a Software Engineer before progressing to Senior Research Engineer, a position she held for more than seven years. This foundation in software engineering and research, followed by leadership roles across healthcare technology and product engineering, has shaped a career spanning technical innovation and large-scale engineering management. At Syneos Health, Raya joins at a time when the company is expanding the role of AI and technology across its operations. Her mandate will center on strengthening the engineering capabilities supporting this strategy, bringing together AI, engineering and technology delivery to improve agility, precision and intelligence in addressing customer challenges. She is an alumna of the Birla Institute of Technology and Science, Pilani (BITS Pilani). Syneos Health is a fully integrated biopharmaceutical solutions organisation focused on accelerating customer success. The company combines clinical, commercial and real-world insights to help address evolving market needs and support the delivery of therapies to patients. Its professionals bring together knowledge of patient and physician behaviours, market dynamics, technology and advanced business practices. Syneos Health positions technology and cross-functional expertise as important enablers in helping customers advance the development and commercialisation of therapies.

Applied Clinical Trials

Aug 19th, 2026

Syneos Health expands AI ecosystem with three new platform partnerships.

Syneos Health expands AI ecosystem with three new platform partnerships. New collaborations with Causaly, Databricks, and Microsoft anchor a broader push to embed artificial intelligence directly into clinical trial decision-making and operational workflows. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development." Syneos Health has announced the continued expansion of its artificial intelligence (AI) ecosystem, detailing three platform partnerships designed to embed AI into core clinical development workflows.[1] The three partnerships each target a distinct layer of the clinical development stack. Through a new collaboration with Causaly, Syneos is applying agentic, evidence-based scientific reasoning to accelerate protocol strategy development, feasibility planning, and competitive trial intelligence. Causaly's platform surfaces evidence from a proprietary knowledge graph combining biomedical research and commercial insights. According to the company, the integration has reduced the time it takes to derive insights for study strategy and design by approximately 50%. The partnership with Databricks focuses on the data infrastructure layer. By leveraging the Databricks Data and AI Platform, Syneos has developed a near real-time view of clinical operations that reduces the time from source data capture to review-ready insight from days to hours, enabling faster intervention and more efficient trial execution. The Microsoft collaboration, which builds on a relationship that began in 2023, extends AI adoption through productivity and workflow tools. Syneos has used Microsoft Power Apps and other tools to develop more than 280 agents that integrate with Microsoft 365 Copilot to streamline workflows and support faster decision-making across the organization. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development," said Mike Montello, chief digital and information officer at Syneos Health, in a company press release. Together, the three partnerships are designed to create what Syneos Health describes as a unified intelligence environment - connecting operational, clinical, and real-world data across the development lifecycle. The company noted that all capabilities are deployed with human oversight and governance to ensure responsible use in regulated environments. A broader conversation about AI and site readiness. The Syneos announcement reflects a pattern Applied Clinical Trials has been tracking closely: sponsor investment in AI is accelerating, but questions about how that technology reaches sites - and whether it actually fits their workflows - remain unresolved. In a recent with ACT, Liz Beatty, co-founder and chief strategy officer at Inato, addressed that tension directly.[2] Beatty argued that the industry has consistently made the mistake of building technology for sponsors rather than for sites. "We need to stop, and instead think: how can I enable sites to use this technology to become more efficient and effective in clinical trials, which then helps my trial and my company - not the other way around," she said. On where AI is delivering measurable enrollment impact, Beatty pointed to real-time patient data as the most significant shift. Rather than relying on feasibility questionnaires and sponsor-discounted estimates, AI tools can now identify which specific patients at a given site currently meet study criteria. In a chronic obstructive pulmonary disease case study, than those that did not, and 100% of sites using the tool were able to successfully screen and enroll patients. Looking ahead, Beatty pointed to a structural shift she sees gaining momentum: sponsors moving away from trial-by-trial site planning toward program or cross-asset planning, building deeper site partnerships across multiple studies. This represents a dynamic that could meaningfully change how enrollment bottlenecks are addressed before a trial even begins. References

News Break! Middle East

Aug 18th, 2026

Syneos Health advances ai-powered clinical ecosystem to optimize trial performance and speed decision-making.

Syneos Health advances ai-powered clinical ecosystem to optimize trial performance and speed decision-making. Expanding set of partners and proprietary insights strengthens operational performance. MORRISVILLE, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) - Syneos Health(R), a leading fully integrated biopharmaceutical solutions organization, today announced the continued advancement of its AI ecosystem - a unified, enterprise approach that embeds artificial intelligence (AI) directly into the core of clinical development. By combining deep therapeutic expertise, healthcare professional intelligence and modern AI technologies, Syneos Health is helping sponsors navigate an increasingly complex development landscape. Grounded in decades of clinical and commercial experience, Syneos Health's differentiated AI approach focuses on integrating advanced capabilities into critical decision points across protocol design, feasibility, enrollment planning, site activation, monitoring and operational oversight. This enables teams to anticipate risk earlier, reduce friction across workflows and make faster, more informed decisions that improve study performance. "Our priority is AI that works inside the complexity of clinical trials. By combining advanced AI with a deep understanding of sites, physicians, patients and the operational dynamics that shape trial performance, we're unlocking new opportunities for speed, clarity and quality," said Mike Montello, Chief Digital and Information Officer, Syneos Health. "When technology is applied precisely at critical decision points, teams can anticipate risk earlier to accelerate development." Enterprise AI and Data Platforms Syneos Health is building a future ready ecosystem bringing together capabilities combining scientific expertise, connected data and evidence, and AI-enabled execution. This integrated approach creates a unified intelligence environment that enables faster, more informed decisions across the clinical development lifecycle. * Causaly - Syneos Health's new collaboration with Causaly applies agentic, evidence-based scientific reasoning to enable faster protocol strategy development, feasibility planning and competitive trial intelligence. Built specifically for the life sciences sector, Causaly's Agentic Research surfaces evidence from a proprietary knowledge graph combining biomedical research and commercial insights. By accelerating analysis of complex biomedical literature and emerging data, Syneos Health teams have reduced the time it takes to derive insights for study strategy and design by approximately 50%. * Databricks - Using Databricks enables Syneos Health to create a more powerful, unified intelligence environment that brings together operational, clinical and real-world data to advance modern clinical development. Leveraging the Databricks Data + AI Platform, Syneos Health has developed a continuous, near real-time view of clinical operations that reduces the time from source data capture to review-ready insight from days to hours, enabling faster intervention and more efficient trial execution. * Microsoft - Building on its long-standing collaboration that began in 2023, Syneos Health is driving AI adoption through its integration with Microsoft. Specifically, Syneos Health has used Microsoft Power Apps and other tools to develop more than 280 agents that integrate with Microsoft 365 Copilot to improve productivity, streamline workflows and support faster, more confident decision-making across the company. Complementing these foundational capabilities are frontier agentic AI solutions and proprietary Syneos Health insights embedded directly within clinical workflows. Together, they help improve predictability, reduce operational complexity, and drive more precise, scalable trial performance. These capabilities are deployed with strong human oversight and governance, ensuring responsible use in regulated environments. "What differentiates Syneos Health is our ability to redesign how clinical development decisions are made through the combination of scientific intelligence, connected evidence, operational expertise and AI-enabled execution across the development lifecycle," said Michael Brooks, Chief Operating Officer, Syneos Health. "By grounding AI in deep clinical expertise and real-world experience, we help sponsors reduce complexity, make better-informed decisions and ultimately deliver better outcomes for patients." About Syneos Health Syneos Health(R) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. News Break Middle East translate unique clinical, commercial and real world insights into outcomes to address modern market realities. News Break Middle East bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together News Break Middle East share diverse insights, use the latest technologies and apply advanced business practices to speed its customers' delivery of important therapies to patients. Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment. Press/Media Contact: Meg Byers Director, External Communications [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. News Break Middle East do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MarketBeat

Aug 12th, 2026

Inovio Pharmaceuticals (NASDAQ:INO) releases quarterly earnings results, beats expectations by $0.15 EPS.

Inovio Pharmaceuticals (NASDAQ:INO) releases quarterly earnings results, beats expectations by $0.15 EPS. August 12, 2026 Key points. * Inovio beat earnings expectations: The company reported a quarterly loss of $0.07 per share, $0.15 better than the consensus estimate of a $0.22 loss. * INO-3107 remains on track for FDA review: The treatment's October 30, 2026 PDUFA date is intact, and Inovio is advancing launch preparations, though accelerated approval and final timing remain uncertain. * Funding remains a concern: Inovio ended the quarter with $36.7 million in cash and expects about $18 million in operational cash burn during the third quarter; a July equity offering is expected to fund operations into late Q1 2027, excluding additional capital raises. * Five stocks we like better than Inovio Pharmaceuticals. Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15, FiscalAI reports. Here are the key takeaways from Inovio Pharmaceuticals' conference call: * Positive Sentiment: INO-3107's FDA review remains on track for the October 30, 2026 PDUFA date; late-cycle review and pre-licensure inspections are complete, with only one reported inspection observation that the company believes it has addressed. * Positive Sentiment: Inovio is advancing launch preparations for INO-3107, including label negotiations expected to begin in September, medical science liaison activities, and a commercialization agreement with Syneos Health. If approved, the company expects seven years of orphan-drug market exclusivity. * Negative Sentiment: The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, and feedback on the confirmatory-trial design remains outstanding. The company continues to characterize approval and launch timing as potential outcomes rather than assured results. * Negative Sentiment: Inovio ended the quarter with $36.7 million in cash, cash equivalents, and short-term investments, and expects approximately $18 million of operational net cash burn in Q3. July's $18.3 million equity offering extends funding into late Q1 2027 and through a potential launch, but the company noted that this projection excludes future capital raises. * Positive Sentiment: Partner ApolloBio reported positive pivotal Phase III results for VGX-3100 in cervical dysplasia, meeting its primary efficacy endpoint and supporting plans for a potential regulatory filing in China. Inovio also reported encouraging preclinical progress for its DPROT platform in hemophilia A and other rare diseases. Inovio Pharmaceuticals price performance. Inovio Pharmaceuticals stock traded up $0.00 during mid-day trading on Wednesday, hitting $0.77. 3,060,340 shares of the company were exchanged, compared to its average volume of 2,293,542. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98. The company has a market capitalization of $63.35 million, a P/E ratio of -0.53 and a beta of 1.52. The business's 50 day simple moving average is $1.04 and its two-hundred day simple moving average is $1.31. Wall Street analyst weigh in. Several equities analysts recently issued reports on INO shares. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, June 21st. HC Wainwright lowered their target price on Inovio Pharmaceuticals from $3.00 to $2.50 and set a "neutral" rating on the stock in a report on Monday, June 1st. Weiss Ratings upgraded Inovio Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 29th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $3.25. Discover more Track Market Trends Stock split calculator Earnings screener tool Institutional trading of Inovio Pharmaceuticals. A number of large investors have recently made changes to their positions in INO. Millennium Management LLC raised its position in shares of Inovio Pharmaceuticals by 468.7% in the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company's stock valued at $4,616,000 after buying an additional 1,625,653 shares during the last quarter. Vanguard Group Inc. boosted its position in Inovio Pharmaceuticals by 35.0% during the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company's stock worth $6,348,000 after acquiring an additional 703,727 shares during the last quarter. 683 Capital Management LLC acquired a new stake in Inovio Pharmaceuticals during the fourth quarter worth approximately $433,000. OMERS ADMINISTRATION Corp purchased a new stake in Inovio Pharmaceuticals in the 4th quarter worth approximately $388,000. Finally, Geode Capital Management LLC grew its stake in Inovio Pharmaceuticals by 40.7% in the 4th quarter. Geode Capital Management LLC now owns 769,356 shares of the biopharmaceutical company's stock worth $1,340,000 after acquiring an additional 222,609 shares during the period. Institutional investors and hedge funds own 26.79% of the company's stock. About Inovio Pharmaceuticals. Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats. Central to Inovio's platform is its SynCon(R) technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra(R) electroporation device, designed to enhance cellular uptake and expression of DNA vaccines. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Inovio Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list. While Inovio Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Syneos Health